Advertisement

Neuroscience and Behavioral Physiology

, Volume 49, Issue 1, pp 153–158 | Cite as

The Role of the Interaction between the NMDA and Dopamine Receptor Genes in Impaired Recognition of Emotional Expression in Schizophrenia

  • M. V. AlfimovaEmail author
  • V. E. Golimbet
  • G. I. Korovaitseva
  • T. V. Lezheiko
  • D. V. Tikhonov
  • T. K. Ganisheva
  • N. B. Berezin
  • A. A. Snegireva
  • T. K. Shemyakina
Article
  • 4 Downloads

Objectives. To seek the genetic mechanisms of impairments to the recognition of emotions, which is a sign of schizophrenia which degrades social adaptation of patients. This search was based on the view that the interaction between the dopaminergic and glutamatergic systems has a role in the pathogenesis of schizophrenia. The effects of the interaction between the polymorphic C366G locus in the gene encoding the NR2B subunit of the NMDA receptor – GRIN2B – the polymorphic loci in the dopamine receptor genes ANKK1/DRD2 Taq1A and DRD4 48-VNTR on the recognition of emotional expressions were studied. Materials and methods. The effects of the interaction between GRIN2B and DRD2 were studied in cohorts of 237 patients and 235 healthy subjects; those between GRIN2B and DRD4 were studied in cohorts of 268 and 208, respectively. Results and conclusions. Both effects reached significance in the combined cohorts of patients and healthy subjects (GRIN2B × DRD2, F = 4.12, p = 0.043; GRIN2B × DRD4, F = 6.43, p = 0.012). The effect of the interaction between the polymorphic loci in the GRIN2B and DRD2 genes on the recognition of expressed emotions in schizophrenia patients was confirmed. In patients with the less effective allele of the DRD2 gene and not bearing the minor allele of the GRIN2B gene, results were close to normal, while the genotype containing the minor alleles of both genes produced the worst results. This result is consistent with concepts of the possible role of the hypofunction of NMDA receptors and D2-mediated regulation of their activity in the production of schizophrenia endotypes such as the recognition of expressed emotions.

Keywords

GRIN2B DRD2 DRD4 recognition of emotions epistatic effects psychosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    C. Kohler, J. Walker, E. Martin, K. Healey, and P. Moberg, “Facial emotion perception in schizophrenia: a meta-analytic review,” Schizophr. Bull., 36, No. 5, 1009–1019 (2010),  https://doi.org/10.1093/schbul/sbn192.CrossRefGoogle Scholar
  2. 2.
    C. Kohler, L. Hoffman, L. Eastman, K. Healey, and P. Moberg, “Facial emotion perception in depression and bipolar disorder: a quantitative review,” Psychiatry Res., 188, No. 3, 303–309 (2011),  https://doi.org/10.1016/j.psychres.2011.04.019.CrossRefGoogle Scholar
  3. 3.
    L. Collin, J. Bindra, M. Raju, C. Gillberg, and H. Minnis, “Facial emotion recognition in child psychiatry: A systematic review,” Res. Dev. Disabil., 34, No. 5, 1505–1520 (2013),  https://doi.org/10.1016/j.ridd.2013.01.008.CrossRefGoogle Scholar
  4. 4.
    B. Cuthbert, “Translating intermediate phenotypes to psychopathology: the NIMH Research Domain Criteria,” Psychophysiology, 51, No. 12, 1205–1206 (2014),  https://doi.org/10.1111/psyp.12342.CrossRefGoogle Scholar
  5. 5.
    E. Weiss, H. Freudenthaler, A. Fink, et al., “Differential influence of 5-HTTLPR – polymorphism and COMT Val158Met – polymorphism on emotion perception and regulation in healthy women,” J. Int. Neuropsychol. Sol., 20, No. 05, 516–524 (2014),  https://doi.org/10.1017/S135561771400023X.CrossRefGoogle Scholar
  6. 6.
    B. Zhu, C. Chen, R. Moyzis, et al., “Genetic variations in the dopamine system and facial expression recognition in healthy Chinese college students,” Neuropsychobiology, 65, No. 2, 83–89 (2012),  https://doi.org/10.1159/000329555.CrossRefGoogle Scholar
  7. 7.
    M. Defrancesco, H. Niederstätter, W. Parson, et al., “Influence of serotonin transporter genotype and catechol-O-methyltransferase Val158Met polymorphism on recognition of emotional faces,” J. Int. Neuropsychol. Sol., 17, No. 06, 1014–1020 (2011),  https://doi.org/10.1017/s135561771100097x.CrossRefGoogle Scholar
  8. 8.
    B. Gohier, C. Senior, J. Radua, et al., “Genetic modulation of the response bias towards facial displays of anger and happiness,” Eur. Psychiatry, 29, No. 4, 197– 202 (2014),  https://doi.org/10.1016/j.eurpsy.2013.03.003.CrossRefGoogle Scholar
  9. 9.
    G. Tamm, K. Kreegipuu, and J. Harro, “Perception of emotion infacial stimuli: The interaction of ADRA2A and COMT genotypes, and sex,” Progr. Neuropsychopharmacol. Biol. Psychiatry, 64, 87–95 (2016),  https://doi.org/10.1016/j.pnpbp.2015.07.012.CrossRefGoogle Scholar
  10. 10.
    A. Tylec, K. Kucharska-Pietura, W. Jeleniewicz, A. Czernikiewicz, and M. Stryjecka-Zimmer, “Functional polymorphism of genes inactivating catecholamines and emotional deficits in paranoid schizophrenia,” Psychiatr. Polska, 44, 207–219 (2010).Google Scholar
  11. 11.
    M. V. Alfimova, V. E. Golimbet, G. I. Korovaitseva, T. V. Lezheiko, L. I. Abramova, E. V. Aksenova, and M. I. Bolgov, “Effects of a polymorphism of the 5-HTTLPR serotonin transporter gene on the recognition of facial emotional expressions in schizophrenia,” Zh. Nevrol. Psikhiat., 114, No. 1, 42–48 (2014).Google Scholar
  12. 12.
    A. Marsh, E. Finger, B. Buzas, et al., “Impaired recognition of fear facial expressions in 5-HTTLPR S-polymorphism carriers following tryptophan depletion,” Psychopharmacology, 189, No. 3, 387–394 (2006),  https://doi.org/10.1007/s00213-006-0581-2.CrossRefGoogle Scholar
  13. 13.
    N. Antypa, H. Cerit, A. Kruijt, F. Verhoeven, and A. Van der Does, “Relationships among 5-HTT genotype, life events and gender in the recognition of facial emotions,” Neuroscience, 172, 303–313 (2011),  https://doi.org/10.1016/j.neuroscience.2010.10.042.CrossRefGoogle Scholar
  14. 14.
    E. Székely, C. Herba, P. Arp, et al., “Recognition of scared faces and the serotonin transporter gene in young children: the Generation R Study,” J. Child Psychol. Psychiatry, 52, No. 12, 1279–1286 (2011),  https://doi.org/10.1111/j.1469-7610.2011.02423.x.CrossRefGoogle Scholar
  15. 15.
    M. Owens, I. Goodyer, P. Wilkinson, et al., “5-HTTLPR and early childhood adversities moderate cognitive and emotional processing in adolescence,” PLoS One, 7, No. 11, 48482 (2012),  https://doi.org/10.1371/journal.pone.0048482.CrossRefGoogle Scholar
  16. 16.
    A. Koizumi, N. Kitagawa, H. Kondo, et al., “Serotonin transporter gene-linked polymorphism affects detection of facial expressions,” PLoS One, 8, No. 3, 59074 (2013),  https://doi.org/10.1371/journal.pone.0059074.CrossRefGoogle Scholar
  17. 17.
    B. Bediou, F. Asri, J. Brunelin, et al., “Emotion recognition and genetic vulnerability to schizophrenia,” Brit. J. Psychiatry, 191, No. 2, 126–130 (2007),  https://doi.org/10.1192/bjp.bp.106.028829.CrossRefGoogle Scholar
  18. 18.
    M. Alfimova, L. Abramova, A. Barhatova, et al., “Facial affect recognition deficit as a marker of genetic vulnerability to schizophrenia,” Span. J. Psychol., 12, No. 01, 46–55 (2009),  https://doi.org/10.1017/s1138741600001463.CrossRefGoogle Scholar
  19. 19.
    A. Ruocco, J. Reilly, L. Rubin, et al., “Emotion recognition deficits in schizophrenia-spectrum disorders and psychotic bipolar disorder: Findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study,” Schizophr. Res., 158, No. 1–3, 105–112 (2014),  https://doi.org/10.1016/j.schres.2014.07.001.CrossRefGoogle Scholar
  20. 20.
    K. Allott, S. Rice, C. Bartholomeusz, et al., “Emotion recognition in unaffected fi rst-degree relatives of individuals with fi rst-episode schizophrenia,” Schizophr. Res., 161, No. 2–3, 322–328 (2015),  https://doi.org/10.1016/j.schres.2014.12.010.CrossRefGoogle Scholar
  21. 21.
    C. Corcoran, J. Keilp, J. Kayser, et al., “Emotion recognition deficits as predictors of transition in individuals at clinical high risk for schizophrenia: a neurodevelopmental perspective,” Psychol. Med., 45, No. 14, 2959–2973 (2015),  https://doi.org/10.1017/s0033291715000902.CrossRefGoogle Scholar
  22. 22.
    T. Greenwood, D. Braff, G. Light, et al., “Initial heritability analyses of endophenotypic measures for schizophrenia,” Arch. Gen. Psychiatry, 64, No. 11, 1242 (2007), https://doi.org/10.1001/archpsyc.64.11.1242–1250.Google Scholar
  23. 23.
    D. Glahn, J. Williams, D. McKay, et al., “Discovering schizophrenia endophenotypes in randomly ascertained pedigrees,” Biol. Psychiatry, 77, No. 1, 75–83 (2015),  https://doi.org/10.1016/j.biopsych.2014.06.027.CrossRefGoogle Scholar
  24. 24.
    T. Greenwood, G. Light, N. Swerdlow, A. Radant, and D. Braff, “Association analysis of 94 candidate genes and schizophrenia-related endophenotypes,” PLoS One, 7, No. 1, 29630 (2012),  https://doi.org/10.1371/journal.pone.0029630.CrossRefGoogle Scholar
  25. 25.
    T. Greenwood, N. Swerdlow, R. Gur, et al., “Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia,” Am. J. Psychiatry, 170, No. 5, 521–532 (2013),  https://doi.org/10.1176/appi.ajp.2012.12020186.CrossRefGoogle Scholar
  26. 26.
    M. Laruelle, W. Frankle, R. Narendran, L. Kegeles, and A. Abi-Dargham, “Mechanism of action of antipsychotic drugs: From dopamine D2 receptor antagonism to glutamate NMDA facilitation,” Clin. Ther., 27, 16–24 (2005),  https://doi.org/10.1016/j.clinthera.2005.07.017.CrossRefGoogle Scholar
  27. 27.
    F. Iasevoli, C. Tomasetti, E. Buonaguro, and A. de Bartolomeis, “The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment,” Curr. Neuropharmacol., 12, No. 3, 219–238 (2014),  https://doi.org/10.2174/1570159X12666140324183406.CrossRefGoogle Scholar
  28. 28.
    O. Howes, R. McCutcheon, and J. Stone, “Glutamate and dopamine in schizophrenia: An update for the 21st century,” J. Psychopharmacol., 29, No. 2, 97–115 (2015),  https://doi.org/10.1177/0269881114563634.CrossRefGoogle Scholar
  29. 29.
    V. I. Litvinenko and M. M. Odinak, “Pathogenetic grounds for formation of cognitive and psychotic impairments in Parkinson’s disease,” Zh. Nevrol. Psikhiat., 104, No. 4, 72–76 (2004).Google Scholar
  30. 30.
    C. Cepeda, V. Andre, E. Jocoy, and M. Levine, “NMDA and dopamine: A. M. diverse mechanisms applied to interacting receptor systems,” in: The Biology of the NMDA Receptor, A. M. Vandongen (ed.), Taylor & Francis Group, Boca Raton (2008); pp. 41–57.Google Scholar
  31. 31.
    M. Martina and R. Bergeron, “D1 and D4 dopaminergic receptor interplay mediates coincident G protein-independent and dependent regulation of glutamate NMDA receptors in the lateral amygdala,” J. Neurochem., 106, No. 6, 2421–2435 (2008),  https://doi.org/10.1111/j.1471-4159.2008.05584.x.CrossRefGoogle Scholar
  32. 32.
    N. Allen, S. Bagade, M. McQueen, J. Ioannidis, F. Kavvoura, M. Khoury, R. Tanzi, and L. Bertram, “Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database,” Nat. Genet., 40, No. 7, 827–834 (2008),  https://doi.org/10.1038/ng.171.CrossRefGoogle Scholar
  33. 33.
    J. Thompson, N. Thomas, A. Singleton, et al., “D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele,” Pharmacogenetics, 7, No. 6, 479–484 (1997),  https://doi.org/10.1097/00008571-199712000-00006.CrossRefGoogle Scholar
  34. 34.
    R. P. Ebstein, “The molecular genetic architecture of human personality: beyond self-report questionnaires,” Mol. Psychiatry, 11, No. 5, 427–445 (2006),  https://doi.org/10.1038/sj.mp.4001814.CrossRefGoogle Scholar
  35. 35.
    F. Mori, M. Ribolsi, H. Kusayanagi, et al., “Genetic variants of the NMDA receptor influence cortical excitability and plasticity in humans,” J. Neurophysiol., 106, No. 4, 1637–1643 (2011),  https://doi.org/10.1152/jn.00318.2011.CrossRefGoogle Scholar
  36. 36.
    C. Weickert, S. Fung, V. Catts, et al., “Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia,” Mol. Psychiatry, 18, No. 11, 1185–1192 (2012),  https://doi.org/10.1038/mp.2012.137.CrossRefGoogle Scholar
  37. 37.
    M. V. Alfimova, V. E. Golimbet, G. I. Korovaitseva, et al., “The C366G Polymorphism of the GRIN2B gene and verbal episodic memory: absence of an association in schizophrenia,” Genetika, 52, No. 6, 713–717 (2016).PubMedGoogle Scholar
  38. 38.
    M. Monakhov, V. Golimbet, L. Abramova, V. Kaleda, and V. Karpov, “Association study of three polymorphisms in the dopamine D2 receptor gene and schizophrenia in the Russian population,” Schizophr. Res., 100, No. 1–3, 302–307 (2008),  https://doi.org/10.1016/j.schres.2008.01.007.CrossRefGoogle Scholar
  39. 39.
    M. Alfimova, G. Korovaitseva, T. Lezheiko, and V. Golimbet, “Interaction effects of the COMT and DRD4 genes with anxiety-related traits on selective attention,” Span. J. Psychol., 17 (2014),  https://doi.org/10.1017/sjp.2014.46.
  40. 40.
    A. Petronis, H. Van Tol, J. Lichter, K. Livak, and J. Kennedy, “The D4 dopamine receptor gene maps on 11p proximal to HRAS,” Genomics, 18, No. 1, 161–163,  https://doi.org/10.1006/geno.1993.1445.
  41. 41.
    R. Wallwork, R. Fortgang, R. Hashimoto, et al., “Searching for a consensus fi ve-factor model of the Positive and Negative Syndrome Scale for Schizophrenia,” Schizophr. Res., 137, No. 1–3, 246–250 (2012),  https://doi.org/10.1016/j.schres.2012.01.031.CrossRefGoogle Scholar
  42. 42.
    A. Comparelli, A. De Carolis, V. Corigliano, et al., “Symptom correlates of facial emotion recognition impairment in schizophrenia,” Psychopathology, 47, No. 1, 65–70 (2014),  https://doi.org/10.1159/000350453.CrossRefGoogle Scholar
  43. 43.
    Y. Li, D. Xi, J. Roman, Y. Huang, and W. Gao, “Activation of glycogen synthase kinase-3 is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex,” J. Neurosci., 29, No. 49, 15551–15563 (2009),  https://doi.org/10.1523/JNEUROSCI.3336-09.2009.CrossRefGoogle Scholar
  44. 44.
    F. Gardoni and C. Bellone, “Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and addiction diseases,” Front. Cell. Neurosci., 9, 25 (2015),  https://doi.org/10.3389/fncel.2015.00025.CrossRefGoogle Scholar
  45. 45.
    T. Ohtsuki, K. Sakurai, H. Dou, et al., “Mutation analysis of the NMDAR2B (GRIN2B) gene in schizophrenia,” Mol. Psychiatry, 6, No. 2, 211–216 (2001),  https://doi.org/10.1038/sj.mp.4000808.CrossRefGoogle Scholar
  46. 46.
    D. Li and L. He, “Association study between the NMDA receptor 2B subunit gene (GRIN2B) and schizophrenia: A HuGE review and meta-analysis,” Genet. Med., 9, No. 1, 4–8 (2007),  https://doi.org/10.1097/01.gim.0000250507.96760.4b.CrossRefGoogle Scholar
  47. 47.
    A. E. Gareeva, D. F. Zakirov, and E. K. Khusnutdinova, “Analysis of associations of polymorphic variants of the GRIN2B gene with paranoid schizophrenia and the efficacy of treatment with typical neuroleptics in Russians and Tartars from the Republic of Bashkortostan,” Genetika, 49, No. 9, 1106–1113 (2013).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • M. V. Alfimova
    • 1
    Email author
  • V. E. Golimbet
    • 1
  • G. I. Korovaitseva
    • 1
  • T. V. Lezheiko
    • 1
  • D. V. Tikhonov
    • 1
  • T. K. Ganisheva
    • 2
  • N. B. Berezin
    • 2
  • A. A. Snegireva
    • 2
  • T. K. Shemyakina
    • 2
  1. 1.Scientific Center for Mental HealthMoscowRussia
  2. 2.Alekseev Psychiatric Clinical Hospital No. 1, Moscow Health DepartmentMoscowRussia

Personalised recommendations